Next 10 |
2024-05-16 08:17:27 ET More on Regulus Therapeutics Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD Seeking Alpha’s Quant Rating on Regulus Therapeutics Read the full article on Seeking Alpha For further details see: Re...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...
2024-05-09 17:39:34 ET More on Regulus Therapeutics Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial informatio...
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disea...
2024-05-07 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can...
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. ...
2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series PR Newswire SAN DIEGO , April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...
2024-04-10 12:51:42 ET Summary Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction of cysts. Additional results from cohort 3 of...
2024-04-09 17:06:43 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics Read the full article on Seeking Alpha For...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disea...